A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities

Biomaterials

Volumn 31, Issue 27, 2010, Pages 7115-7123

  Wang, Zhe ^a   Ho, Paul C ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Angiogenesis; Cancer metastasis; Combination therapy; Combretastatin A4; Nanocapsule; Paclitaxel

Indexed keywords

AMPHIPHILICS; ANGIOGENESIS; ANTIANGIOGENESIS; ANTICANCER ACTIVITIES; BIODISTRIBUTIONS; CANCER CELLS; CANCER METASTASIS; CANCER THERAPY; CELLULAR UPTAKE; COMBINATION THERAPY; DRUG DELIVERY SYSTEM; IN-VIVO; LIVER METASTASIS; MATRIX; NARROW SIZE DISTRIBUTIONS; NEOVASCULATURE; PACLITAXEL; PROLIFERATION INHIBITION; SMALL PARTICLE SIZE; THERAPEUTIC EFFECTS; TUMOR CELLS; TUMOR VASCULATURE; TUMOR XENOGRAFTS;

CELL DEATH; CELL PROLIFERATION; DRUG DELIVERY; LIVER; PATHOLOGY; TUMORS;

NANOCAPSULES;

COMBRETASTATIN A4; NANOCAPSULE; PACLITAXEL; ANTINEOPLASTIC AGENT; COMBRETASTATIN A4 PHOSPHATE; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY FLUID; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; TUMOR CELL; TUMOR VASCULARIZATION; ANIMAL; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; SECONDARY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MICE; NANOCAPSULES; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; STILBENES;

EID: 77954384048     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.05.075     Document Type: Article

References (33)

1. Steeg P.S. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006, 12:895-904.
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
3. Dorrell M.I., Aguilar E., Scheppke L., Barnett F.H., Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci USA 2007, 104:967-972.
4. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl J Med 1971, 285:1182-1186.
5. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Engl J Med 2004, 350:2335-2342.
6. Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4:423-436.
7. Tran J., Master Z., Yu J.L., Rak J., Dumont D.J., Kerbel R.S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002, 99:4349-4354.
8. Blagosklonny M.V. Antiangiogenic therapy and tumor progression. Cancer Cell. 2004, 5:13-17.
9. Yang Q.W., Tian Y.F., Liu S.Q., Zeine R., Chlenski A., Salwen H.R., et al. Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma. Cancer Res 2007, 67:1716-1724.
10. Henke E., Perk J., Vider J., de Candia P., Chin Y., Solit D.B., et al. Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat Biotechnol 2008, 26:91-100.
11. Uno T., Takeda K., Kojima Y., Yoshizawa H., Akiba H., Mittler R.S., et al. Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 2006, 12:693-698.
12. Kerbel R., Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002, 2:727-739.
13. Sengupta S., Eavarone D., Capila I., Zhao G.L., Watson N., Kiziltepe T., et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005, 436:568-572.
14. Wang Z., Chui W.K., Ho P.C. Design of a multifunctional PLGA nanoparticulate drug delivery system: evaluation of its physicochemical properties and anticancer activity to malignant cancer cells. Pharm Res 2009, 26:1162-1171.
15. Deutsch H.M., Glinski J.A., Hernandez M., Haugwitz R.D., Narayanan V.L., Suffness M., et al. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor-activity. J Med Chem 1989, 32:788-792.
16. Woodrow K.A., Cu Y., Booth C.J., Saucier-Sawyer J.K., Wood M.J., Saltzman W.M. Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mat 2009, 8:526-533.
17. Murphy E.A., Majeti B.K., Barnes L.A., Makale M., Weis S.M., Lutu-Fuga K., et al. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci USA 2008, 105:9343-9348.
18. Cheng J., Teply B.A., Sherifi I., Sung J., Luther G., Gu F.X., et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28:869-876.
19. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
20. Satchi-Fainaro R., Puder M., Davies J.W., Tran H.T., Sampson D.A., Greene A.K., et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 2004, 10:255-261.
21. Chaplin D.J., Pettit G.R., Hill S.A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999, 19:189-195.
22. Liu Z., Chen K., Davis C., Sherlock S., Cao Q.Z., Chen X.Y., et al. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 2008, 68:6652-6660.
23. van Vlerken L.E., Duan Z., Little S.R., Seiden M.V., Amiji M.M. Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol Pharm 2008, 5:516-526.
24. Barberaguillem E., Smith I., Weiss L. Cancer cell traffic in the liver.1. Growth-kinetics of cancer-cells after portal-vein delivery. Int J Cancer 1992, 52:974-977.
25. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006, 6:688-701.
26. Pasquier E., Carre M., Pourroy B., Camoin L., Rebai O., Briand C., et al. Antiangiogenic activity of paclitaxel is associated with its cytostatic effect, mediated by the initiation but not completion of a mitochondrial apoptotic signaling pathway. Mol Cancer Ther 2004, 3:1301-1310.
27. McGown A.T., Fox B.W. Structural and biochemical-comparison of the anti-mitotic agents colchicine, combretastatin-A4 and amphethinile. Anti-Cancer Drug Des 1989, 3:249-254.
28. Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?. Science 2006, 312:1171-1175.
29. Benny O., Fainaru O., Adini A., Cassiola F., Bazinet L., Adini I., et al. An orally delivered small-molecule formulation with antiangiogenic and anticancer activity. Nat Biotechnol 2008, 26:799-807.
30. Peer D., Karp J.M., Hong S., FaroKhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007, 2:751-760.
31. Dobrovolskaia M.A., Germolec D.R., Weaver J.L. Evaluation of nanoparticle immunotoxicity. Nat Nanotechnol 2009, 4:411-414.
32. Yoo H.S., Oh J.E., Lee K.H., Park T.G. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm Res 1999, 16:1114-1118.
33. Tong R., Cheng J.J. Ring-opening polymerization-mediated controlled formulation of polylactide-drug nanoparticles. J Am Chem Soc 2009, 131:4744-4754.